Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2015 · 10-Q
Revenue$1.07M$1.07M−1.8% vs Q2 2014 Net Income-$906.95K-$906.95KN/M vs Q2 2014 EPS Diluted-$0.02-$0.02N/M vs Q2 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$614,439N/M Free Cash Flowderived-$655,643N/M Margins · derivedGross margin-3.6%−0.4 pt vs Q2 2014
Operating margin-95.8%+0.5 pt vs Q2 2014
Net margin-85.1%+0.3 pt vs Q2 2014
ended Dec 31, 2014 · filed Feb 17, 2015 · 48 d after period end